DE60225545D1 - Verstärkte herstellung rekombinanter proteine mitthsenden säugerzellen - Google Patents

Verstärkte herstellung rekombinanter proteine mitthsenden säugerzellen

Info

Publication number
DE60225545D1
DE60225545D1 DE60225545T DE60225545T DE60225545D1 DE 60225545 D1 DE60225545 D1 DE 60225545D1 DE 60225545 T DE60225545 T DE 60225545T DE 60225545 T DE60225545 T DE 60225545T DE 60225545 D1 DE60225545 D1 DE 60225545D1
Authority
DE
Germany
Prior art keywords
recombinant proteins
protein
production
expression
transfection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60225545T
Other languages
English (en)
Other versions
DE60225545T2 (de
Inventor
Yves Durocher
Sylvie Perret
Phuong Lan Pham
Amine Kamen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Publication of DE60225545D1 publication Critical patent/DE60225545D1/de
Application granted granted Critical
Publication of DE60225545T2 publication Critical patent/DE60225545T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE60225545T 2001-05-07 2002-05-07 Verstärkte herstellung rekombinanter proteine mittels transienter transfektion von in suspension wachsenden säugerzellen Expired - Lifetime DE60225545T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28879001P 2001-05-07 2001-05-07
US288790P 2001-05-07
PCT/CA2002/000683 WO2002090533A2 (en) 2001-05-07 2002-05-07 Enhanced production of recombinant proteins by transient transfection of suspension-growing mammalian cells

Publications (2)

Publication Number Publication Date
DE60225545D1 true DE60225545D1 (de) 2008-04-24
DE60225545T2 DE60225545T2 (de) 2009-04-02

Family

ID=23108658

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60225545T Expired - Lifetime DE60225545T2 (de) 2001-05-07 2002-05-07 Verstärkte herstellung rekombinanter proteine mittels transienter transfektion von in suspension wachsenden säugerzellen

Country Status (7)

Country Link
US (2) US10421950B2 (de)
EP (1) EP1390511B1 (de)
AT (1) ATE389022T1 (de)
AU (1) AU2002257440A1 (de)
CA (1) CA2446185C (de)
DE (1) DE60225545T2 (de)
WO (1) WO2002090533A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217566B2 (en) * 2003-03-24 2007-05-15 Invitrogen Corporation Attached cell lines
JP2006121995A (ja) * 2004-10-29 2006-05-18 Tokyo Medical & Dental Univ Ｅｂｎａ１変異体
WO2006096989A2 (en) * 2005-03-17 2006-09-21 National Research Council Of Canada Expression vectors containing a truncated epstein barr nuclear antigen 1 lacking the gly-gly-ala domain for enhanced transient gene expression
CA2624685C (en) 2005-10-28 2014-06-03 Ulrich Goepfert Protein expression in rodent cells
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK1994155T4 (da) 2006-02-13 2022-07-25 Daiichi Sankyo Co Ltd Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering
CN101501216B (zh) * 2006-03-06 2013-10-02 胡玛基因公司 制备重组人凝血酶的方法
US8076139B1 (en) 2006-05-19 2011-12-13 Leinco Technologies, Inc. Processes and compositions for transfecting Chinese hamster ovary (CHO) cells
WO2009137911A1 (en) 2008-05-15 2009-11-19 National Research Counsil Of Canada Process, vectors and engineered cell lines for enhanced large-scale transfection
CA2725919A1 (en) * 2008-05-28 2009-12-03 Roland Antonius Paulus Romijn Method for the production of proteins or protein fragments
AU2009321508B2 (en) 2008-11-03 2015-03-12 Adc Therapeutics Sa Antibodies that specifically block the biological activity of a tumor antigen
CN103492418B (zh) 2011-03-31 2016-06-29 阿莱斯亚生物疗法股份有限公司 针对肾相关抗原1的抗体及其抗原结合片段
CN103620034B (zh) 2011-04-13 2016-12-14 加拿大国家研究委员会 具有来自IFNα2的SAR元件的表达系统
BR112014016723A2 (pt) 2012-01-09 2018-07-24 Alethia Biotherapeutics Inc. método para o tratamento de câncer de mama
AU2013293062A1 (en) 2012-07-19 2014-07-24 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
US9920121B2 (en) 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
EP3134439B1 (de) 2014-04-21 2018-12-26 Millennium Pharmaceuticals, Inc. Anti-psyk-antikörpermoleküle und verwendung davon für eine auf syk abzielende therapie
FR3025107B1 (fr) 2014-08-29 2018-10-05 Calixar Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations
CN110023755A (zh) 2016-12-01 2019-07-16 诺伯特·格雷茨 用于组织结构的可视化的装置和方法
FR3063730B1 (fr) 2017-03-09 2021-09-17 Centre Nat Rech Scient Composes-clips surfactants pour l'extraction et la stabilisation en solution de proteines membranaires
CN113025648B (zh) * 2019-12-09 2023-06-02 广东菲鹏制药股份有限公司 Expi293细胞瞬时表达目标蛋白的方法及其应用
CN114410682A (zh) * 2022-02-08 2022-04-29 美康生物科技股份有限公司 一种293t细胞瞬时表达目标蛋白的方法及其应用
CN117265049A (zh) * 2023-09-12 2023-12-22 武汉爱博泰克生物科技有限公司 利用反应管培养细胞表达高通量重组抗体的方法及装置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804374A (en) * 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
US5550036A (en) * 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
US5024947A (en) * 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
DE4138621A1 (de) * 1991-11-25 1993-06-17 Boehringer Ingelheim Int Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg
EP0760861A1 (de) * 1994-05-20 1997-03-12 The Board Of Trustees Of The Leland Stanford Junior University Selbststandiges replikationsystem fur zellen von saugetieren
WO1998037185A2 (en) 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vectors for controlled gene expression
ATE270341T1 (de) * 1997-06-19 2004-07-15 Gen Hospital Corp Kompakte replikons des epstein-barr-virus.
US6210922B1 (en) * 1998-11-30 2001-04-03 National Research Council Of Canada Serum free production of recombinant proteins and adenoviral vectors
US7723102B2 (en) * 2000-09-28 2010-05-25 Bayer Corporation Enhanced transfection system

Also Published As

Publication number Publication date
EP1390511A2 (de) 2004-02-25
WO2002090533A3 (en) 2003-05-22
WO2002090533A2 (en) 2002-11-14
EP1390511B1 (de) 2008-03-12
AU2002257440A1 (en) 2002-11-18
US10858629B2 (en) 2020-12-08
WO2002090533A9 (en) 2002-12-27
US20050170450A1 (en) 2005-08-04
CA2446185C (en) 2013-06-18
DE60225545T2 (de) 2009-04-02
US10421950B2 (en) 2019-09-24
CA2446185A1 (en) 2002-11-14
US20200010808A1 (en) 2020-01-09
ATE389022T1 (de) 2008-03-15

Similar Documents

Publication Publication Date Title
DE60225545D1 (de) Verstärkte herstellung rekombinanter proteine mitthsenden säugerzellen
US7794976B2 (en) Methods and materials for expression of a recombinant protein
US20200354752A1 (en) Engineered cas9 systems for eukaryotic genome modification
DK1576182T4 (da) Produktkvalitetsforbedring ved fremgangsmåde med dyrkning af pattedyreceller til proteinfremstilling
MXPA04004634A (es) Expresion policistronica de anticuerpos.
WO2007012144A1 (en) Compositions and methods for growth of pluripotent cells
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
MX9605542A (es) Produccion de proteinas y liberacion de proteinas.
MX9206376A (es) Liberacion de proteinas por terapia genica
RU2003131342A (ru) Способы культивирования цирковирусов
BRPI9916095B8 (pt) célula e linhagem de célula expressando uma proteína heteróloga
EP1702071A4 (de) Transaktivierungssystem für säugerzellen
CA3163463A1 (en) High fidelity spcas9 nucleases for genome modification
Cappello Genetic production of synthetic protein polymers
JO1694B1 (en) New chemical products
CN102325881A (zh) 用于用动物细胞大量生产源自外源基因的蛋白质的表达载体及其应用
CN102392047A (zh) 一种适用于哺乳动物细胞的双顺反子表达载体及其应用
Ferrari et al. Biosynthesis of protein polymers
WO2000006713A3 (en) Methods for recombinant protein production in mammalian cells comprising co-expression with fetuin
Gao et al. Transfection and expression of exogenous gene in laying hens oviduct in vitro and in vivo
ATE266094T1 (de) Produktion des proteins ingap mit hoher expressionsrate
CN112824530A (zh) 一种hek293f悬浮细胞高效电转染方法
TWI316958B (de)
Søndergaard Drosophila cells can be grown to high cell densities in a bioreactor
GEISSE et al. Novartis Pharma Inc.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition